A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis
| Status: | Completed |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 3/14/2019 |
| Start Date: | June 2012 |
| End Date: | February 2013 |
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of Escalating Doses of Oral Itacitinib in Subjects With Stable, Chronic Plaque Psoriasis
This is a study of itacitinib in patients with chronic plaque psoriasis. This study will
evaluate safety and efficacy parameters of itacitinib.
evaluate safety and efficacy parameters of itacitinib.
Inclusion Criteria:
- Subjects with chronic plaque psoriasis aged 18 to 75 who have had insufficient
response to topical agents, and who meet the psoriasis assessment expectations as
defined in the study protocol
Exclusion Criteria:
- Females who are pregnant or breastfeeding
- Men and women who cannot comply with requirements to avoid fathering a child or
becoming pregnant, respectively
- Subjects treated with leflunomide or other biological therapies to treat psoriasis and
all JAK-STAT inhibitors within 12 weeks prior to first dose of study drug
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials